| Literature DB >> 28386138 |
Saeedeh Shenavandeh1, Mahyar Yousefipour Haghighi1, Mohammad Ali Nazarinia2.
Abstract
BACKGROUND: Systemic sclerosis (SSc) is a chronic disease with microvascular damage. Nailfold capillaroscopy is a non-invasive method used for evaluating capillaries in SSc. Its findings could be related to the internal organ involvement and SSc course. In this study, we aimed to determine the association of the capillaroscopic patterns of nailfold capillaries with the disease subtypes of SSc, disease duration, and clinical manifestations.Entities:
Keywords: clinical manifestations; nailfold capillaroscopy; systemic sclerosis
Year: 2017 PMID: 28386138 PMCID: PMC5380768 DOI: 10.5114/reum.2017.66683
Source DB: PubMed Journal: Reumatologia ISSN: 0034-6233
Demographic data, disease information, and disease subgroups’ frequency
| Variable | All patients ( | DcSSc ( | LcSSc ( | Early DcSSc ( | Late DcSSc ( | Early LcSSc ( | Late LcSSc ( | |
|---|---|---|---|---|---|---|---|---|
| Gender | Male no. (%) | 11 (15.7%) | 4 (26.7%) | 7 (12.7%) | 1 (12.5%) | 3 (42.9%) | 4 (11.8%) | 3 (14.3%) |
| Female no. (%) | 59 (84.3%) | 11 (73.3%) | 48 (87.3%) | 7 (87.5%) | 4 (57.1%) | 30 (88.2%) | 18 (85.7%) | |
| Age (years old) mean ± SD | 41.5 ±11 | 40 ±13.5 | 41.9 ±10.3 | 32.5 ±5 | 48.6 | 42.6 ±9.6 | 40.6 ±11.5 | |
| Disease Duration (years) mean ± SD | 4.8 ±6 | 3.5 ±5 | 5.1 ±5.8 | 0.8 ±0.3 | 6.6 ±6 | 1.9 ±1.2 | 10.3 ±6.5 | |
| RP Duration (years) mean ± SD | 6 ±7 | 3.4 ±5 | 6.7 ±7.4 | 1.2 ±0.9 | 5.8 ±6.6 | 3.1 ±4.6 | 12.6 ±7.3 |
RP – Raynaud’s phenomenon; SD – standard deviation
Capillaroscopic scleroderma patterns and its components’ frequency
| Variable | All patients ( | DcSSc ( | LcSSc ( | Early DcSSc ( | Late DcSSc ( | Early LcSSc ( | Late LcSSc ( | |
|---|---|---|---|---|---|---|---|---|
| Scleroderma pattern | 68 (97.1%) | 15 (100%) | 53 (96.4%) | 8 (100%) | 7 (100%) | 33 (97.1%) | 20 (95.2%) | |
| Capillary pattern | “early” scleroderma pattern | 16 (22.9%) | 1 (6.7%) | 15 (27.3%) | 1 (12.5%) | 0 (0%) | 14 (41.2%) | 1 (4.8%) |
| “active” scleroderma pattern | 34 (48.6%) | 8 (53.3%) | 26 (47.3%) | 5 (62.5%) | 3 (42.9%) | 16 (47.15%) | 10 (47.6%) | |
| “late” scleroderma pattern | 18 (25.7%) | 6 (40%) | 12 (21.8%) | 2 (25%) | 4 (57.1%) | 4 (11.8%) | 8 (38.1%) | |
| “nonspecific” pattern | 2 (2.9%) | 0 (0%) | 2 (3.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (9.5%) | |
| Abnormal capillary distribution | 55 (78.6%) | 14 (93.3%) | 41 (74.5%) | 8 (100%) | 6 (85.7%) | 21 (61.8%) | 20 (95.2%) | |
| Subtle change | 15 (21.4%) | 0 (0%) | 15 (27.3%) | 0 (0%) | 0 (0%) | 11 (32.4%) | 4 (19%) | |
| tortuosity | 2 (11.4%) | 0 (0%) | 8 (14.5%) | 0 (0%) | 0 (0%) | 6 (17.6%) | 2 (9.5%) | |
| crossing | 2 (12.9%) | 0 (0%) | 9 (16.4%) | 0 (0%) | 0 (0%) | 7 (20.6%) | 2 (9.5%) | |
| mixed | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Capillary anomalies | 65 (92.9%) | 12 (80%) | 53 (96.4%) | 6 (75%) | 6 (85.7%) | 33 (97.1%) | 20 (95.2%) | |
| widening | 6 (8.6%) | 2 (13.3%) | 4 (7.3%) | 1 (12.5%) | 1 (14.3%) | 3 (8.8%) | 1 (4.8%) | |
| meandering | 2 (2.9%) | 0 (0%) | 2 (3.6%) | 0 (0%) | 0 (0%) | 1 (2.9%) | 1 (4.8%) | |
| dilation | 65 (92.9%) | 13 (86.7%) | 52 (94.5%) | 7 (87.5%) | 6 (85.7%) | 34 (100%) | 18 (85.7%) | |
| neoangiogenesis | 26 (37.1%) | 9 (60%) | 17 (30.9%) | 4 (50%) | 5 (71.4%) | 8 (23.5%) | 9 (42.9%) | |
| bizarre | 6 (8.6%) | 0 (0%) | 6 (10.9%) | 0 (0%) | 0 (0%) | 3 (8.8%) | 3 (14.3%) | |
| Giant loop (> 0.05 mm) | 44 (62.9%) | 7 (46.7%) | 37 (67.3%) | 5 (62.5%) | 2 (28.6%) | 26 (76.5%) | 11 (52.4%) | |
| Reduced capillary density < 7/mm | 49 (70%) | 14 (93.3%) | 35 (63.6%) | 7 (87.5%) | 7 (100%) | 21 (61.8%) | 13 (60.7%) | |
| Avascular area | 27 (38.6%) | 7 (46.7%) | 20 (36.4%) | 3 (37.5%) | 4 (57.1%) | 11 (32.4%) | 9 (42.9%) | |
| Hemorrhage | 46 (65.7%) | 7 (46.7%) | 39 (70.9%) | 5 (62.5%) | 2 (28.6%) | 26 (76.5%) | 13 (61.9%) | |
| Elongated capillary | 10 (14.3%) | 1 (6.7%) | 9 (16.4%) | 1 (12.5%) | 0 (0%) | 7 (20.6%) | 2 (9.5%) | |
| Abnormal blood flow | 53 (85%) | 7 (58.3%) | 46 (92%) | 2 (28.6%) | 4 (60%) | 3 (9.1%) | 1 (5.9%) |
LcSSc – limited cutaneous systemic sclerosis; DcSSc – diffuse cutaneous systemic sclerosis
The skin score and clinical manifestation frequency in all patients and two subtypes of SSc (DcSSc and LcSSc) separately
| Variable | Total | DcSSc | LcSSc | ||||
|---|---|---|---|---|---|---|---|
|
| no. (%) |
| no. (%) |
| no. (%) | ||
| Skin score | < 15 | 70 | 56 (80%) | 15 | 4 (26.7%) | 55 | 52 (94.5%) |
| 15 ≤ &< 30 | 70 | 11 (15.7%) | 15 | 8 (53.3%) | 55 | 3 (5.5%) | |
| ≥ 30 | 70 | 3 (4.3%) | 15 | 3 (20%) | 55 | 0 (0%) | |
| Telangiectasia | 70 | 39 (55.7) | 15 | 9 (60%) | 55 | 30 (54.5%) | |
| Calcinosis | 70 | 1 (1.4%) | 15 | 0 (0%) | 55 | 1 (1.8%) | |
| Peripheral vascular problem | 70 | 49 (70%) | 15 | 12 (80%) | 55 | 37 (67.3%) | |
| RP needing vasodilator | 70 | 55 (79.7%) | 15 | 12 (80%) | 55 | 43 (79.6%) | |
| Pitting scar | 70 | 32 (45.7%) | 15 | 11 (73.3%) | 55 | 21 (38.2%) | |
| Digital tip ulcer | 70 | 18 (25.7%) | 15 | 5 (33.3%) | 55 | 13 (23.6%) | |
| Digital gangrene | 70 | 2 (2.9) | 15 | 0 (0%) | 55 | 2 (3.6%) | |
| Limitation of FTP | 70 | 16 (22.9%) | 15 | 10 (66.7%) | 55 | 6 (10.9%) | |
| Proximal muscle weakness | 70 | 2 (2.9%) | 15 | 2 (14.3%) | 55 | 0 (0%) | |
| GI abnormality | 70 | 53 (75.7%) | 15 | 13 (86.7%) | 55 | 40 (72.7%) | |
| Dysphagia | 70 | 23 (33.3%) | 15 | 7 (46.7%) | 55 | 16 (29.6%) | |
| Heart burn | 70 | 44 (63.8%) | 15 | 11 (73.3%) | 55 | 33 (61.1%) | |
| Difficult swallowing | 70 | 22 (31.9%) | 15 | 5 (33.3%) | 55 | 17 (31.9%) | |
| Lung involvement | 70 | 38 (54.3%) | 15 | 11 (73.3%) | 55 | 27 (49.1%) | |
| Pulmonary hypertension | 70 | 3 (4.3%) | 15 | 0 (0%) | 55 | 3 (5.5%) | |
| Dyspnea | No dyspnea | 70 | 48 (68.6%) | 15 | 8 (53.3%) | 55 | 40 (72.7%) |
| At rest | 8 (11.4%) | 5 (33.3%) | 3 (5.5%) | ||||
| At walk | 14 (20%) | 2 (13.3%) | 12 (21.8%) | ||||
| Rales | 70 | 17 (24.3%) | 15 | 6 (40%) | 55 | 11 (20%) | |
| HRCT involvement | 51 | 40 (78.4%) | 12 | 10 (83.3%) | 39 | 30 (76.9%) | |
| Heart problem | 70 | 3 (4.3%) | 15 | 15 (100%) | 55 | 3 (5.5%) | |
| Hypertension | 70 | 1 (1.4%) | 15 | 0 (0%) | 55 | 1 (1.8%) | |
| Renal failure | 70 | 0 (0%) | 15 | 0 (0%/) | 55 | 0 (0%) | |
| Immunosuppressive administered | 63 | 27 (45%)S | 12 | 5 (41.7%) | 48 | 22 (45.8%) | |
| Hypothyroidism | 70 | 9 (12.9%) | 15 | 3 (20%) | 55 | 6 (10.9%) | |
RA – Raynaud’s phenomenon; FTP – finger-to-palm; GI – gastrointestinal; LcSSc – limited cutaneous systemic sclerosis; DcSSc – diffuse cutaneous systemic sclerosis
Including: ground glass opacities, reticular patterns, or honeycombing
The association between the SSc subtypes/subgroups with scleroderma patterns of capillaroscopy
| SSc subtype | Scleroderma pattern of capillaroscopy |
|
| |||
|---|---|---|---|---|---|---|
| “early” | “active” | “late” | “non specific” | |||
| Early DcSSc | 1 (12.5%) | 5 (62.5%) | 2 (25%) | 0 (0%) | 0.007 | 70 |
| Late DcSSc | 0 (0%) | 3 (42.9%) | 4 (57.1%) | 0 (0%) | ||
| Early LcSSc | 14 (41.2%) | 16 (47.1%) | 4 (11.8%) | 0 (0%) | ||
| Late LcSSc | 1 (4.8%) | 10 (47.6%) | 8 (38.1%) | 2 (9.5%) | ||
SSc – systemic sclerosis; LcSSc – limited cutaneous systemic sclerosis; DcSSc – diffuse cutaneous systemic sclerosis
Detailed analysis of the significant associations between clinical manifestation and para-clinical data and capillaroscopic patterns in 1) all patients, 2) DcSSc and 3) LcSSc besides 4) early and 5) late SSc analyzed separately
| Variable | Scleroderma pattern of capillaroscopy |
| Total | |||
|---|---|---|---|---|---|---|
| “early” | “active” | “late” | “non specific” | |||
| Telangiectasia in all SSc cases | 3 (18%) | 23 (67.6%) | 13 (72.2%) | 0 (0%) | 0.001 | 70 |
| Telangiectasia in early SSc | 2 (13.3%) | 12 (57.1%) | 3 (50%) | 0 (0%) | 0.023 | 42 |
| Telangiectasia in LcSSc | 3 (20%) | 18 (69.2%) | 9 (75) | 0 (0%) | 0.002 | 55 |
| Pitting scar in all SSc cases | 3 (18%) | 16 (47%) | 13 (72%) | 0 (0%) | 0.007 | 70 |
| Pitting scar in LcSSc | 2 (9.1%) | 11 (45.5%) | 8 (45.5%) | 0 (0%) | 0.018 | 55 |
| Limitation of FTP in all SSc cases | 1 (6.2%) | 6 (17.6%) | 9 (50%) | 0 (0.0%) | 0.013 | 70 |
| Limitation of FTP in DcSSc | 1 (100%) | 3 (37.5%) | 6 (100%) | 0 (0%) | 0.025 | 15 |
| Rales in all SSc cases | 0 (0.0%) | 10 (29.4%) | 7 (38.9%) | 0 (0.0%) | 0.020 | 70 |
| Low FEV1 (< 70%) in LcSSc | 0 (0.0%) | 3 (50.0%) | 3 (100%) | 0 (0.0%) | 0.024 | 15 |
| Low FEV1 (< 70%) in early DcSSc | 0 (0.0%) | 1 (25%) | 2 (100%) | 0 (0%) | 0.048 | 11 |
SSc – systemic sclerosis; LcSSc – limited cutaneous systemic sclerosis; DcSSc – diffuse cutaneous systemic sclerosis; FTP – finger-to-palm; FEV1 – forced expiratory volume in one second % of vital capacity
Fig. 1Tortuous capillaries (A), elongated capillaries (B), scleroderma patterns (C, D, E, F).